Regulatory approval

Published by the Health Canada. Approved

Health Canada approved rituximab for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) in combination with CHOP chemotherapy.

This is written in the approval document as:

RITUXAN (rituximab for injection) is indicated for the treatment of patients with CD20 positive, diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy.

Citation

Hoffmann-La Roche Limited. Rituxan (rituximab) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071131.PDF. Revised June 2023. Accessed June 2025.

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine

Contributions

Date Contributor Description
2024-10-30 Van Allen lab Initial access of FDA approvals